ES2162813T3 - Uso de 3,5-diamino-6-(2,3-diclorofenil)-1,2,4-triazina en la preparacion de un farmaco para el tratamiento de ciertos tipos de dolor y edema. - Google Patents

Uso de 3,5-diamino-6-(2,3-diclorofenil)-1,2,4-triazina en la preparacion de un farmaco para el tratamiento de ciertos tipos de dolor y edema.

Info

Publication number
ES2162813T3
ES2162813T3 ES93904225T ES93904225T ES2162813T3 ES 2162813 T3 ES2162813 T3 ES 2162813T3 ES 93904225 T ES93904225 T ES 93904225T ES 93904225 T ES93904225 T ES 93904225T ES 2162813 T3 ES2162813 T3 ES 2162813T3
Authority
ES
Spain
Prior art keywords
diamino
triazine
diclorophenil
pharmaco
edema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93904225T
Other languages
English (en)
Inventor
Meire Nakamura-Craig
Michael John Leach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2162813T3 publication Critical patent/ES2162813T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

3,5DIAMINO-6-(2,3-DICLOROFENIL)-1,2,4-TRIACINA Y SUS SALES DE ADICION DE ACIDO FARMACEUTICA Y VETERINARIAMENTE ACEPTABLES PUEDEN USARSE PARA PREVENIR O TRATAR EL DOLOR O EL EDEMA.
ES93904225T 1992-02-19 1993-02-18 Uso de 3,5-diamino-6-(2,3-diclorofenil)-1,2,4-triazina en la preparacion de un farmaco para el tratamiento de ciertos tipos de dolor y edema. Expired - Lifetime ES2162813T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929203483A GB9203483D0 (en) 1992-02-19 1992-02-19 Anti-inflammatory compounds

Publications (1)

Publication Number Publication Date
ES2162813T3 true ES2162813T3 (es) 2002-01-16

Family

ID=10710643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93904225T Expired - Lifetime ES2162813T3 (es) 1992-02-19 1993-02-18 Uso de 3,5-diamino-6-(2,3-diclorofenil)-1,2,4-triazina en la preparacion de un farmaco para el tratamiento de ciertos tipos de dolor y edema.

Country Status (18)

Country Link
US (1) US5712277A (es)
EP (1) EP0626851B1 (es)
KR (1) KR950700067A (es)
AT (1) ATE204476T1 (es)
AU (1) AU684711B2 (es)
CA (1) CA2129043C (es)
CY (1) CY2299B1 (es)
DE (1) DE69330638T2 (es)
DK (1) DK0626851T3 (es)
ES (1) ES2162813T3 (es)
GB (2) GB9203483D0 (es)
GR (1) GR3036958T3 (es)
IL (1) IL104775A (es)
MX (1) MX9300927A (es)
NZ (1) NZ249197A (es)
PT (1) PT626851E (es)
TW (1) TW226331B (es)
WO (1) WO1993016700A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
US20080096965A1 (en) * 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
WO2016198878A1 (en) * 2015-06-12 2016-12-15 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
US4310551A (en) * 1979-03-19 1982-01-12 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
EP0021121B1 (en) * 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds

Also Published As

Publication number Publication date
GB9414348D0 (en) 1994-09-07
CY2299B1 (en) 2003-07-04
JPH07503968A (ja) 1995-04-27
DE69330638D1 (de) 2001-09-27
CA2129043A1 (en) 1993-09-02
IL104775A0 (en) 1993-06-10
US5712277A (en) 1998-01-27
DE69330638T2 (de) 2002-06-27
AU684711B2 (en) 1998-01-08
WO1993016700A1 (en) 1993-09-02
EP0626851A1 (en) 1994-12-07
AU3509293A (en) 1993-09-13
KR950700067A (ko) 1995-01-16
NZ249197A (en) 1997-05-26
DK0626851T3 (da) 2001-12-03
CA2129043C (en) 2004-01-27
GB2277265A (en) 1994-10-26
GR3036958T3 (en) 2002-01-31
ATE204476T1 (de) 2001-09-15
JP3713271B2 (ja) 2005-11-09
MX9300927A (es) 1994-08-31
TW226331B (es) 1994-07-11
GB2277265B (en) 1996-01-10
EP0626851B1 (en) 2001-08-22
PT626851E (pt) 2002-02-28
GB9203483D0 (en) 1992-04-08
IL104775A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
TW273550B (es)
IL101960A0 (en) Substituted 3-aminoquininuclidines
ZA941530B (en) Use of lamotrigine in the treatment of neuro-AIDS
MY106528A (en) Method of treating impotence.
GB9203483D0 (en) Anti-inflammatory compounds
ES2091941T3 (es) Potenciador del efecto antineoplasico y agente antineoplasico.
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
WO1992007564A3 (en) Method of treating demyelinating disease
ES2124926T3 (es) Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.
GB2282326A (en) Use of 3,5-diamino-6-(2,3 dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence,tolerance and sensitization of drugs
BR9607663A (pt) Uso de penciclovir para o tratamento de herpes-virus 8 humano
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
CY2338B1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626851

Country of ref document: ES